Monday to Friday: 9am – 6pm | Saturday: 9am – 1pm | Sunday & PH: Closed
1 month+
Ideal Timing Before Therapy
<0.1%
MRONJ Risk — Oral Osteoporosis
1–17%
MRONJ Risk — IV Oncology Dose
NUCOH 2025
Singapore Guideline
TLDR
Dental clearance for bisphosphonate therapy is a structured assessment — not a routine clean — performed before you start antiresorptive medication, or before any invasive dental treatment while you're already on it. Your dentist examines for silent infections, reviews your medication history, and treats anything that would carry higher risk later. For most patients on oral osteoporosis drugs, this takes one to two appointments. The risk of a serious complication (MRONJ) at standard doses is under 0.1% — genuinely low, but worth knowing about before you start.
Last medically reviewed: August 2026 · Reviewed by Dr Jonathan Liu, Principal Dentist and Founder
Your rheumatologist, endocrinologist, or oncologist has referred you for dental clearance before starting a bisphosphonate or antiresorptive medication — and you're not entirely sure what that means or what to expect. This guide explains what dental clearance for bisphosphonate therapy involves, what the risks are, and how long the process takes.
What dental clearance for bisphosphonate therapy involves
Dental clearance is a focused assessment, not a routine check-up. When your physician refers you, your dentist is looking for specific conditions that would carry a higher risk of complications once antiresorptive therapy begins.
Step 1
Clinical examination and X-rays
Your dentist examines every tooth, gum tissue, and surrounding bone. A full panoramic X-ray is taken if not recently done — this identifies periapical abscesses, deep bone loss, and failing root canals not visible on the surface.
Step 2
Medication review
Your dentist needs to know which drug, whether oral or IV, and whether you're also taking corticosteroids or have conditions affecting healing such as diabetes. This determines your risk category before any treatment decision.
Step 3
Treatment triage
Any tooth likely to require extraction in the near future — not just those causing problems now — is flagged. Treating before therapy begins avoids a higher-risk extraction later. Teeth manageable without surgery are handled that way first.
Step 4
Clearance documentation
Once treatment is complete and healing confirmed, your dentist provides a clearance record for your prescribing physician. Where all findings are low-risk and no treatment is required, this can often be confirmed at the first visit.
For most patients on oral bisphosphonates for osteoporosis with no other risk factors, clearance requires one to two appointments. Where extractions are needed, allow four to six weeks of socket healing before antiresorptive therapy starts where timing allows. If your medication start date is imminent, prioritise the medication over delaying it for non-urgent dental issues — your prescribing physician and dentist will agree the safest approach together.
Why it matters — what bisphosphonates do to bone healing
Bisphosphonates work by suppressing osteoclasts — the cells responsible for breaking down and remodelling old bone. This is what makes them effective at reducing fracture risk in osteoporosis and controlling bone metastases in cancer.
The same mechanism creates a specific risk in the jaw. The jawbones are uniquely exposed to the oral environment through gum tissue and tooth roots, and they depend on continuous bone remodelling to repair the microtrauma of daily use. When osteoclast activity is suppressed, this repair process is slower and less reliable.
The clinical consequence is MRONJ — medication-related osteonecrosis of the jaw — in which bone fails to heal after a wound and exposed bone persists for eight weeks or more. Dental clearance before therapy begins gives your dentist the opportunity to resolve potential triggers while healing is straightforward. For a full breakdown of MRONJ risk by drug type and staging, see our guide to tooth extraction on bisphosphonates.
If you're already on bisphosphonates and haven't had a dental clearance
More common than expected. Many patients have been on oral bisphosphonates for osteoporosis for years without a specific clearance assessment. The approach depends on your current oral health status.
Mouth in good condition
No active infection, gum disease controlled — routine dental care continues without modification. Your medication history is noted and careful technique applied for any procedures.
Problems found
Active infection, failing restorations, or bone loss — treat as soon as possible using the most conservative approach. Root canal treatment to retain a tooth that might otherwise need extraction is often the preferred path.
IV oncology-dose antiresorptives
Zoledronic acid (Zometa) or denosumab (Xgeva) for cancer — see a dentist as a matter of priority. The risk profile at these doses is substantially higher. Any invasive procedure requires oncology team input first.
Risk by drug type — a brief summary
Not all bisphosphonates carry the same risk. The two primary variables are route of administration and the underlying condition being treated. Corticosteroid co-prescription, diabetes, and smoking compound risk across all categories.
| Medication | Condition | Route | Est. MRONJ risk |
|---|---|---|---|
| Alendronate (Fosamax) | Osteoporosis | Oral | <0.1% (<4 yrs); ~0.21% (>4 yrs) |
| Risedronate (Actonel) | Osteoporosis | Oral | <0.1% |
| Zoledronic acid (Aclasta) | Osteoporosis | IV, annual | ~0.017–0.35% |
| Denosumab (Prolia) | Osteoporosis | Subcutaneous, 2×/yr | ~0.04–0.3% |
| Zoledronic acid (Zometa) | Cancer | IV, monthly | ~1–17% |
| Denosumab (Xgeva) | Cancer | Subcutaneous, monthly | Comparable to IV oncology |
All figures are estimates from published clinical studies. Individual risk depends on duration, concurrent medications, and overall health.
Ongoing dental care while on antiresorptive therapy
Bisphosphonate therapy does not mean stopping all dental care. For patients on oral osteoporosis doses, routine dentistry continues as normal.
Continues without additional precautions
- Check-ups and X-rays
- Fillings and composite restorations
- Root canal treatment
- Crowns and bridgework
- Scaling and periodontal cleaning
- Denture adjustments
Requires more considered planning
- Tooth extraction — risk assessment, careful technique, 6–8 week follow-up required
- Dental implant placement — individual assessment; generally avoided at oncology doses
- Elective jaw surgery — deferred unless clinically necessary
Singapore Medical Journal guidelines recommend monitoring at least once per year throughout antiresorptive therapy. Your dentist may suggest more frequent appointments depending on your gum health and oral hygiene.
Drug holidays: what the evidence says
Stopping bisphosphonates before dental surgery — sometimes called a drug holiday — was once suggested as a precautionary measure. The AAOMS 2022 position update no longer recommends this routinely for low-risk patients. A 2022 Cochrane systematic review found insufficient evidence that drug holidays reduce MRONJ risk.
For bisphosphonates, the limited benefit is partly pharmacological: the medication remains bound to bone for years after stopping. A brief pause does not meaningfully reduce bone concentrations or restore normal osteoclast activity within a clinically useful window.
Important: denosumab (Prolia / Xgeva)
Do not stop denosumab without consulting your prescribing physician. Missing a dose without a planned transition to bisphosphonate therapy can cause rapid bone loss and vertebral fractures within months.
The NUCOH Modified-Delphi Consensus 2025 and the ACE 2025 Osteoporosis Guideline both support continuing antiresorptive therapy through dental procedures in most cases, with any modification decided jointly between the prescribing physician and the dentist.
"Dental clearance before bisphosphonate therapy is a brief but important checkpoint. For most patients on oral medication for osteoporosis, the process is straightforward and the risk of complications is genuinely low. Where higher-dose IV therapy is involved, or where we find active infection during the clearance visit, early coordination with the prescribing physician makes a real difference to how safely we can manage the patient's oral health through their course of treatment."
Dr Jonathan Liu · Principal Dentist and Founder · BDS (NUS) · SDC Reg. D21395J
Clinical References
- Chua E et al. Dental care for patients receiving antiresorptive agents: a modified Delphi consensus. BMC Oral Health, 2025;25:1706 · PubMed
- Agency for Care Effectiveness (ACE). Osteoporosis — Recognising, Assessing and Managing the Risk of Fractures. MOH Singapore, 2025 · ace-hta.gov.sg
- Chan BH et al. Medication-related osteonecrosis of the jaw in osteoporotic patients. Singapore Med J, 2018;59(2):70–76 · SMJ
- AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw: 2022 Update. J Oral Maxillofac Surg, 2022 · PubMed
- Beth-Tasdogan NH et al. Interventions for managing osteonecrosis of the jaw. Cochrane Database Syst Rev, 2022 · Cochrane
Disclaimer
This article is intended for general educational purposes only and does not constitute medical or dental advice. Individual risk profiles vary significantly — consult your dentist and prescribing physician before making any decisions about dental treatment or antiresorptive medication changes.
Reviewed by Dr Jonathan Liu
Principal Dentist and Founder · Dentalis Singapore
Dr Liu has over 25 years of clinical experience managing patients on antiresorptive and antiangiogenic therapy, coordinating with referring physicians and oncologists across the medically complex patient spectrum. View profile →
Frequently asked questions
Bring the referral letter, a list of all current medications including doses, and your most recent dental X-rays if you have them. Your dentist will arrange any imaging needed. The appointment covers an examination, X-rays, and a review of your medication and health history. Most patients with good oral health require one to two visits for clearance.
Book a dental assessment as soon as possible. At five years, you are at slightly higher risk than a patient under four years on the same drug — but it remains in the low range for standard oral osteoporosis doses. Your dentist will assess your current oral health, identify any areas of concern, and manage them with the most conservative approach appropriate. Waiting does not reduce risk.
Yes. Restorative dentistry — fillings, crowns, root canal treatment — is not affected by bisphosphonate therapy. Elevated caution applies to procedures involving the bone: extraction, implant placement, and elective surgical procedures. Your dentist will note your medication history and apply appropriate technique for any planned work.
It is not too late — but see a dentist as soon as possible. IV oncology-dose zoledronic acid carries a substantially higher MRONJ risk than oral osteoporosis medication. Your dentist will assess your oral health urgently and coordinate any necessary treatment with your oncology team before proceeding with anything invasive. Active infection requires prompt attention.
Not routinely. AAOMS 2022 no longer recommends drug holidays as standard practice for low-risk patients. For oral osteoporosis doses, a brief pause provides little clinical benefit and slightly increases fracture risk. For denosumab (Prolia/Xgeva), do not stop without consulting your prescribing physician — rebound bone loss and fractures can occur within months of a missed dose.
For patients with good oral health, clearance can often be confirmed at the first appointment. If treatment is needed — scaling, fillings, or borderline teeth — allow two to four weeks. If extraction is required, the ideal is four to six weeks of socket healing before antiresorptive therapy begins. Where your start date is imminent, your physician and dentist will discuss the safest approach together.
Related Reading
Referred for Bisphosphonate Dental Clearance?
Book your assessment at Dentalis, Tanjong Pagar.
One to two appointments is all most patients require. We coordinate directly with your prescribing physician where needed, and provide clearance documentation for your referring team. Located at 52 Craig Rd, Tanjong Pagar — accessible from Maxwell MRT.